Synonyms: 3α,5α-tetrahydroprogesterone | 3α,5α-THP | allopregnanolone | SAGE-547 | SAGE547 | Zulresso®
5α-pregnan-3α-ol-20-one is an approved drug (FDA (2019))
Compound class:
Metabolite or derivative
Comment: This steroidal compound behaves as a neuroactive agent with anti-depressant activity in mood disorders [2-3]. Pharmacologically it is a positive allosteric modulator of GABAA receptors.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
As the INN brexanolone (research code SAGE-547), this drug was approved by the FDA in March 2019, indicated for the treatment of moderate to severe postpartum depression [1]. Brexanolone has to be delivered as a continuous i.v. infusion (over a period of 60 hours), and this must only be carried out by a health care provider in a certified health care facility. In the US brexanolone is only available through a restricted distribution program called the Zulresso REMS Program. |